Tag:
Delenex Therapeutics
Latest Headlines
Latest Headlines
Swiss antibody start-up pushes Series A round to $35M
Switzerland's Delenex Therapeutics has beefed up its Series A venture round, bringing the total to close to $35 million as it prepares to dive into clinical studies of its antibodies for inflammatory
ESBATech spin-out Delenex rounds up $14M
Switzerland's Delenex Therapeutics has raised $14 million (CHF 13.5 million) in a Series A round of financing. SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners all
